Abstract:Diabetes mellitus is constantly increasing worldwide. Vascular complications are the most common in the setting of long-standing disease, claiming the greatest burden in terms of morbidity and mortality. Glucotoxicity is involved in vascular damage through different metabolic pathways, such as production of advanced glycation end-products, activation of protein kinase C, polyol pathway activation and production of reactive oxygen species. Vascular complications can be classified according to the calibre of the vessels involved as microvascular (such as diabetic retinopathy, nephropathy and neuropathy) or macrovascular (such as cerebrovascular, coronary and peripheral artery disease). Previous studies showed that the severity of vascular complications depends on duration and degree of hyperglycaemia and, as consequence, early trials were designed to prove that intensive glucose control could reduce the number of vascular events. Unfortunately, results were not as satisfactory as expected. Trials showed good results in reducing incidence of microvascular complications but coronary heart diseases, strokes and peripheral artery diseases were not affected despite optimal glycemia control. In 2008, after the demonstration that rosiglitazone increases cardiovascular risk, FDA demanded stricter rules for marketing glucose-lowering drugs, marking the beginning of cardiovascular outcome trials, whose function is to demonstrate the cardiovascular safety of anti-diabetic drugs. The introduction of new molecules led to a change in diabetes treatment, as some new glucose-lowering drugs showed not only to be safe but also to ensure cardiovascular benefit to diabetic patients. Empaglifozin, a sodium-glucose cotransporter 2 inhibitor, was the first molecule to show impressing results, followed on by glucagon-like peptide 1 receptor agonists, such as liraglutide. A combination of anti-atherogenic effects and hemodynamic improvements are likely explanations of the observed reduction in cardiovascular events and mortality. These evidences have opened a completely new era in the field of glucose-lowering drugs and of diabetes treatment in particular with respect to vascular complications.

Glycation and Glycosylation in Cardiovascular Remodeling: Focus on Advanced Glycation End Products and O-Linked Glycosylations as Glucose-Related Pathogenetic Factors and Disease Markers

O-GlcNAcylation Involvement in High Glucose-Induced Cardiac Hypertrophy Via ERK1/2 and Cyclin D2

Chronic O-GlcNAcylation and Diabetic Cardiomyopathy: The Bitterness of Glucose

An Overview of Glycosylation and its Impact on Cardiovascular Health and Disease

Advanced Glycation End Products: A Sweet Flavor That Embitters Cardiovascular Disease

Glycation in the cardiomyocyte

Mechanisms of diabetic cardiomyopathy and potential therapeutic strategies: preclinical and clinical evidence

Protein glycosylation in cardiovascular health and disease

Advanced glycation end-products: a review

Increased dicarbonyl metabolism in endothelial cells in hyperglycemia induces anoikis and impairs angiogenesis by RGD and GFOGER motif modification

Glycaemic Control and Vascular Complications in Diabetes Mellitus Type 2

AGE-RAGE Axis and Cardiovascular Diseases: Pathophysiologic Mechanisms and Prospects for Clinical Applications

Glycometabolism reprogramming: Implications for cardiovascular diseases

O-linked β-N-acetylglucosamine (O-GlcNAc) modification: Emerging pathogenesis and a therapeutic target of diabetic nephropathy

Advanced Glycation End Products and Diabetic Vascular Complications

The role of glucagon-like peptide-1/GLP-1R and autophagy in diabetic cardiovascular disease

Optimizing glycation control in diabetes: An integrated approach for inhibiting nonenzymatic glycation reactions of biological macromolecules

In vivo glycation-interplay between oxidant and carbonyl stress in bone

A Review on Cellular and Molecular Mechanisms Linked to the Development of Diabetes Complications

Potential Mechanisms and Clinical Implications

Glycation Damage: A Possible Hub for Major Pathophysiological Disorders and Aging